Skip to content

PEAK PHARMACEUTICALS, INC.: 10-Q filed 2013-05-10

What PEAK PHARMACEUTICALS, INC. reported in its quarterly report filed 2013-05-10 (fiscal Q2 2013): 15 published measures, 45 facts as tagged in accession 0001477932-13-002270.

This filing

Form
10-Q (quarterly report)
Filed
2013-05-10
Fiscal period
fiscal Q2 2013
Accession
0001477932-13-002270 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PEAK PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-03-3113,692USD
At 2012-09-308,231USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-03-3148,014USD
At 2012-09-3035,130USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-03-3110,424USD
At 2012-09-304,963USD
At 2012-03-3113,918USD
At 2011-09-304,840USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-3,584USD90
2012-10-01 to 2013-03-31-7,423USD182
2007-12-18 to 2013-03-31-95,322USD1931
2012-01-01 to 2012-03-31-3,462USD91
2011-10-01 to 2012-03-31-7,342USD183

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-10-01 to 2013-03-31-10,049USD182
2007-12-18 to 2013-03-31-85,086USD1931
2011-10-01 to 2012-03-31-9,922USD183

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-10-01 to 2013-03-3115,510USD182
2007-12-18 to 2013-03-3195,510USD1931
2011-10-01 to 2012-03-3119,000USD183

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2013-01-01 to 2013-03-31220,500,000shares90
2012-10-01 to 2013-03-31220,500,000shares182
2012-01-01 to 2012-03-31220,500,000shares91
2011-10-01 to 2012-03-31220,500,000shares183

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2013-01-01 to 2013-03-310USD/shares90
2012-10-01 to 2013-03-310USD/shares182
2012-01-01 to 2012-03-310USD/shares91
2011-10-01 to 2012-03-310USD/shares183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-03-31220,500,000shares
At 2012-09-30220,500,000shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-03-3138,950USD
At 2012-09-3038,950USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2013-03-31-34,322USD
At 2012-09-30-26,899USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2012-10-01 to 2013-03-31-7,423USD182
2007-12-18 to 2013-03-31-95,322USD1931
2011-10-01 to 2012-03-31-7,342USD183

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-03-313,584USD90
2012-10-01 to 2013-03-317,423USD182
2007-12-18 to 2013-03-3195,322USD1931
2012-01-01 to 2012-03-313,462USD91
2011-10-01 to 2012-03-317,342USD183

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2007-12-18 to 2013-03-3161,000USD1931

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2012-10-01 to 2013-03-31-2,626USD182
2007-12-18 to 2013-03-3113,504USD1931
2011-10-01 to 2012-03-312,420USD183

Inspect the source

Entity
PEAK PHARMACEUTICALS, INC. / CIK 0001452804
Captured
SEC response SHA-256
3fd5eb06bfdebffa42021b094c4c379c1efd3c7143204265bf035090db070211

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001452804.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))